Plain-English translation of NCT05815927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether combining (an immunotherapy medication) with a special type of targeted radiation called SABR works better than alone for head and neck cancer that has spread to a small number of locations in the body. Half of the participants will receive only the medication, while the other half will receive both the medication and the targeted radiation. The goal is to see which approach helps people live longer without their cancer getting worse.
Immunotherapy has helped many people with advanced head and neck cancer, but researchers want to know whether adding precise, high-dose radiation to specific tumors might make the treatment even more effective at stopping cancer growth.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the immunotherapy medication alone or the medication combined with targeted radiation. The medication is given as an infusion every 6 weeks for 2 years (17 doses total). If you are in the radiation group, you will also receive SABR treatment to your cancer spots, which is a precise, high-dose radiation delivered over a few sessions. You will have regular follow-up appointments and imaging scans to check how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Belgium